IGF-1 LR3 Research Peptide

Peptora Research Peptide Library

IGF-1 LR3 Research Peptide Overview

IGF-1 LR3 Research Peptide, also known as Long R3 IGF-I, is an engineered analogue of insulin-like growth factor I designed to retain IGF-I receptor activity while interacting much less strongly with IGF-binding proteins. Its altered structure has made it useful in laboratory research examining IGF1R signalling, IGF-binding-protein biology, cellular proliferation, differentiation and experimental growth-factor systems.

Explore Research Materials Sermorelin Overview Tesamorelin Overview Testing & COAs

Analogue overview

What Is the IGF-1 LR3 Research Peptide?

Long R3 IGF-I is a laboratory-engineered analogue of native insulin-like growth factor I. It is commonly abbreviated LR3 IGF-I, Long R3 IGF-I or IGF-1 LR3.

Native mature human IGF-I contains 70 amino acids. Long R3 IGF-I combines an N-terminal extension with an amino-acid substitution near the beginning of the IGF-I sequence. These modifications markedly alter its interaction with IGF-binding proteins while preserving activity at the IGF-I receptor.

IGF-1 LR3 Research Peptide at a Glance

Scientific name: Long R3 insulin-like growth factor I.

Research class: engineered IGF-I analogue.

Length: 83 amino acids.

Native IGF-I: 70 amino acids in the mature peptide.

Key modifications: 13-amino-acid N-terminal extension plus an Arg substitution at position 3 of the IGF-I portion.

Primary research system: IGF-I receptor signalling and IGF-binding-protein biology.

Molecular engineering

How IGF-1 LR3 Differs From Native IGF-I

The name “Long R3” describes two important structural features.

The Long portion refers to an additional 13-amino-acid sequence at the N terminus. The R3 designation refers to replacement of the native residue at position 3 of the IGF-I sequence with arginine.

Native IGF-I

Mature native IGF-I contains 70 amino acids and interacts strongly with multiple IGF-binding proteins.

+13

N-Terminal Extension

Long R3 IGF-I includes an additional 13-amino-acid sequence at its N terminus.

Arginine Substitution

An arginine substitution at position 3 contributes to the analogue's altered binding characteristics.

83 Amino Acids

The engineered analogue therefore contains 83 amino acids in total.

Important distinction: IGF-1 LR3 is not simply another name for native IGF-I. It is a structurally modified IGF-I analogue developed specifically to alter interactions with IGF-binding proteins.

Binding-protein biology

IGF-1 LR3 Research Peptide and IGF-Binding Proteins

One of the most important reasons Long R3 IGF-I appears in experimental research is its substantially reduced affinity for insulin-like growth factor-binding proteins, or IGFBPs.

IGFBPs regulate the distribution, availability and activity of native IGFs. Researchers can therefore use an analogue with reduced IGFBP affinity to investigate how binding proteins influence IGF signalling.

Native IGF-I High IGFBP interaction

→

IGFBPs Binding and sequestration

→

IGF Availability Regulated extracellularly

Long R3 IGF-I Modified analogue

→

Reduced IGFBP Affinity Altered binding interaction

→

IGF1R Research Receptor signalling experiments

Published experimental literature describes Long R3 IGF-I as retaining IGF-I receptor activity while binding much less strongly to IGF-binding proteins.

Receptor signalling

IGF1R Signalling in IGF-1 LR3 Research

The insulin-like growth factor I receptor, or IGF1R, is a receptor tyrosine kinase that participates in signalling networks involving cellular growth, survival, proliferation and differentiation.

Long R3 IGF-I has been used experimentally to examine these pathways while reducing some of the extracellular regulation normally produced by IGF-binding proteins.

IGF1R Activation

Long R3 IGF-I retains activity at the IGF-I receptor despite its altered binding-protein interactions.

Receptor Phosphorylation

Cell experiments have examined IGF1R phosphorylation following exposure to IGF-I analogues.

Intracellular Signalling

IGF1R activation can engage intracellular signalling networks including PI3K/AKT- and MAPK-related pathways.

Cellular Responses

Downstream experimental endpoints include proliferation, differentiation and other cell-type-specific responses.

Cell-culture research

IGF-1 LR3 Research Peptide in Cellular Models

Long R3 IGF-I has been used extensively as an experimental growth factor in cultured-cell systems.

For example, research involving postnatal lung fibroblasts found that Long R3 IGF-I stimulated proliferation at lower concentrations than native IGF-I under the conditions tested. The investigators interpreted the difference as evidence that IGF-binding proteins present in the conditioned medium were limiting native IGF-I activity.

Why Long R3 IGF-I Is Useful Experimentally

If endogenous IGF-binding proteins in a cell-culture system bind native IGF-I, they can complicate interpretation of receptor-level experiments.

An analogue with substantially reduced IGFBP affinity provides researchers with another way to investigate whether observed effects depend on binding-protein regulation.

That makes Long R3 IGF-I a useful experimental probe, not simply a “stronger version” of native IGF-I.

Muscle-cell research

IGF-1 LR3 and Myogenic Cell Research

IGF signalling has been studied extensively in skeletal-muscle cell biology, including proliferation and differentiation of myogenic precursor cells.

Long R3 IGF-I has been used in these systems specifically because its reduced binding-protein affinity allows researchers to investigate the role played by IGFBPs.

One study involving L6 myogenic cells found that IGFBP-3 could suppress both native IGF-I- and Long R3 IGF-I-stimulated proliferation. However, IGFBP-3 affected differentiation responses differently depending on which IGF material was used.

Research interpretation: cellular responses to Long R3 IGF-I can depend on the cell type, receptor environment, binding proteins, experimental concentration and endpoint being measured. Results from one cell system should not automatically be generalized to another.

Animal research

Preclinical IGF-1 LR3 Research

Long R3 IGF-I has also been investigated in multiple animal models, providing evidence that its biological behaviour is not necessarily a simple amplified version of native IGF-I.

In guinea pigs, continuous Long R3 IGF-I exposure altered the fractional weights of several organs while also reducing circulating IGF-I, IGF-II and IGF-binding-protein concentrations. Overall body growth was not significantly stimulated in that experiment.

In another study involving finisher pigs, Long R3 IGF-I reduced average daily gain and food intake and lowered circulating IGFBP-3, endogenous IGF-I, insulin and growth-hormone measures.

Guinea-Pig Research

Experimental exposure altered selected organ measurements and circulating IGF-system markers without significantly increasing overall growth.

Pig Research

Long R3 IGF-I produced endocrine feedback effects and was associated with reduced growth performance under the conditions studied.

Intestinal Models

Newborn-rat research has investigated Long R3 IGF-I in experimental intestinal growth systems.

Species Differences

Different animal models can produce substantially different physiological responses to IGF analogues.

Evidence limits

Why IGF-1 LR3 Research Requires Careful Interpretation

Long R3 IGF-I is frequently discussed online in ways that extend far beyond the evidence available for the analogue itself.

The scientific literature located for this overview consists predominantly of cell-culture, biochemical and animal research. Native IGF-I has a much broader human physiological and clinical literature, but those findings cannot automatically be assigned to Long R3 IGF-I.

✓ Separate native IGF-I evidence from Long R3 IGF-I evidence.

✓ Identify whether evidence is cellular, animal or human.

✓ Keep species-specific results tied to the species studied.

✓ Distinguish IGF1R activity from whole-organism outcomes.

✓ Consider the role of IGF-binding proteins.

✓ Account for cell type and experimental conditions.

✓ Avoid treating proliferation as a universal beneficial endpoint.

✓ Do not convert preclinical evidence into personal-use claims.

Molecular comparison

IGF-1 LR3 Research Peptide vs Native IGF-I

Feature	Native IGF-I	Long R3 IGF-I
Peptide type	Naturally occurring growth factor	Engineered IGF-I analogue
Mature length	70 amino acids	83 amino acids
N-terminal extension	No	13 additional amino acids
Position-3 modification	Native sequence	Arg substitution
IGFBP affinity	Strong interaction	Substantially reduced interaction
IGF1R activity	Yes	Retained

GH/IGF axis

IGF-1 LR3 vs Sermorelin Research

IGF-1 LR3 and sermorelin occupy very different positions in the growth hormone/IGF research axis.

Sermorelin is a GHRH(1-29) peptide that acts upstream through pituitary GHRH receptors and is studied in relation to endogenous GH secretion. Long R3 IGF-I is an engineered analogue of IGF-I and is studied primarily at the IGF/IGF1R level.

Feature	IGF-1 LR3	Sermorelin
Research family	IGF-I analogue	GHRH-related peptide
Primary research target	IGF-I receptor / IGF-binding proteins	GHRH receptor
Position in endocrine axis	IGF signalling level	Upstream pituitary GH regulation
Same mechanism?	No — they investigate different levels of the GH/IGF endocrine system.

See the Sermorelin Research Peptide Overview for GHRH-related research.

GHRH comparison

IGF-1 LR3 vs Tesamorelin Research

Tesamorelin is also upstream of the IGF system. It is a modified GHRH-related peptide whose receptor activity involves pituitary regulation of endogenous growth hormone secretion.

Long R3 IGF-I, by contrast, is an engineered IGF-I analogue designed to interact directly with IGF signalling while reducing binding to IGFBPs.

LR3

Long R3 IGF-I

Engineered IGF-I analogue used to investigate IGF1R and binding-protein biology.

TES

Tesamorelin

Modified GHRH-related peptide investigated through pituitary GHRH receptor signalling.

Explore the Tesamorelin Research Peptide Overview.

Feedback biology

IGF-1 LR3 and Endocrine Feedback Research

Preclinical research illustrates why IGF signalling cannot be understood solely by measuring a single growth endpoint.

In the pig study, Long R3 IGF-I was associated with reductions in plasma GH, endogenous IGF-I, IGFBP-3 and insulin. These findings demonstrate that manipulating one component of the IGF system can alter other endocrine signals through feedback relationships.

The IGF System Is a Regulatory Network

Growth hormone, endogenous IGF-I, IGF-binding proteins, insulin and IGF receptors participate in interconnected physiological systems.

An engineered analogue can therefore produce secondary changes that differ between experimental species and conditions.

This is another reason that Long R3 IGF-I should not be reduced to a simple “more IGF activity” description.

Analytical quality

Testing an IGF-1 LR3 Research Peptide Batch

Because Long R3 IGF-I is a specifically engineered analogue, molecular identity is particularly important when evaluating research material.

A label stating “IGF-1” does not by itself establish that a material is Long R3 IGF-I, native IGF-I or another analogue.

✓ Match documentation to the specific batch.

✓ Confirm the stated molecular identity.

✓ Distinguish Long R3 IGF-I from native IGF-I.

✓ Review purity where reported.

✓ Review measured content where reported.

✓ Confirm the analytical methods used.

✓ Review additional testing only where documented.

✓ Do not transfer results between unrelated batches.

See Peptora's Testing & COAs, Testing Standards and Peptide Purity & Certificates of Analysis Explained.

Research interpretation

How to Evaluate IGF-1 LR3 Research Peptide Evidence

Accurate interpretation starts by identifying exactly which molecule, model and endpoint were studied.

✓ Confirm Long R3 IGF-I was actually used.

✓ Do not substitute native IGF-I literature automatically.

✓ Distinguish receptor signalling from organism-level outcomes.

✓ Identify the relevant IGF-binding proteins.

✓ Note whether research used cultured cells or animals.

✓ Consider species-specific endocrine feedback.

✓ Avoid extrapolating proliferation data to health outcomes.

✓ Keep conclusions within the experiment actually performed.

Research network

Continue Exploring IGF-1 LR3 Research Peptide Topics

Long R3 IGF-I connects with Peptora's GHRH research, GH/IGF-axis education, peptide-testing resources and broader research-peptide library.

IGF-1 LR3 and Related Research Resources

Use related articles to distinguish upstream GHRH signalling from downstream IGF receptor research.

Sermorelin Research Peptide Overview → Tesamorelin Research Peptide Overview → CJC-1295 No DAC Overview → Ipamorelin Research Overview → What Are Research Peptides? → Understanding Peptide Stability → Testing & COAs → Complete Research Library →

IGF-1 LR3 FAQ

IGF-1 LR3 Research Peptide: Frequently Asked Questions

Common research questions about Long R3 IGF-I, native IGF-I, IGF-binding proteins and IGF1R signalling.

What is the IGF-1 LR3 research peptide?

IGF-1 LR3, or Long R3 IGF-I, is an engineered analogue of insulin-like growth factor I with a 13-amino-acid N-terminal extension and an arginine substitution at position 3 of the IGF-I portion.

How many amino acids are in IGF-1 LR3?

Long R3 IGF-I contains 83 amino acids: the 70-amino-acid IGF-I framework plus a 13-amino-acid N-terminal extension.

Is IGF-1 LR3 the same as native IGF-I?

No. Long R3 IGF-I is an engineered analogue. Its structural modifications substantially reduce its affinity for IGF-binding proteins compared with native IGF-I.

Why does IGF-1 LR3 have reduced IGFBP affinity?

The N-terminal extension and position-3 substitution alter interactions with IGF-binding proteins, allowing Long R3 IGF-I to bind them much less strongly while retaining IGF-I receptor activity.

What receptor is studied with IGF-1 LR3?

Long R3 IGF-I is primarily used in research involving the insulin-like growth factor I receptor, or IGF1R, along with the regulatory role of IGF-binding proteins.

Does IGF-1 LR3 have human clinical evidence?

The scientific literature for Long R3 IGF-I is predominantly laboratory, cellular and animal research. Human evidence involving native IGF-I should not automatically be attributed to the Long R3 analogue.

Is IGF-1 LR3 the same as sermorelin?

No. Sermorelin is a GHRH-related peptide acting upstream through pituitary GHRH receptors. Long R3 IGF-I is an engineered IGF-I analogue studied at the IGF receptor and IGF-binding-protein level.

How should an IGF-1 LR3 research batch be evaluated?

Researchers should review batch-specific documentation for molecular identity, purity, measured content and any additional testing actually reported. Particular attention should be paid to distinguishing Long R3 IGF-I from native IGF-I or other IGF analogues.

Research use only

IGF-1 LR3 Research Peptide for Controlled Laboratory Research

This page provides educational information about Long R3 IGF-I, IGF-I receptor signalling, IGF-binding proteins and published laboratory and preclinical research. Findings from cell and animal models do not establish clinical effects in humans.

Peptora Peptide Labs research materials are intended solely for controlled non-clinical laboratory research. They are not intended for human or veterinary consumption, compounding or clinical use. Nothing on this page provides medical advice, dosing or administration guidance or represents that IGF-1 LR3 diagnoses, treats, cures or prevents disease.